Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Exchange Rate Effect (2023 - 2026)

Gyre Therapeutics (GYRE) reported Exchange Rate Effect of $285000.0 for Q1 2026, up 470.0% year-over-year from $50000.0 in Q1 2025, and up 124.41% on a QoQ basis from $127000.0 in Q4 2025.

Gyre Therapeutics (GYRE) has 4 years of Exchange Rate Effect data on file, last reported at $285000.0 in Q1 2026.

  • Quarterly Exchange Rate Effect rose 470.0% year-over-year to $285000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $578000.0 (up 426.55% YoY) and the FY2025 annual result came in at $343000.0, up 225.64% from the prior year.
  • Exchange Rate Effect rose to $285000.0 in Q1 2026 per GYRE's latest filing, from $127000.0 in the prior quarter.
  • Across five years, Exchange Rate Effect topped out at $285000.0 in Q1 2026 and bottomed at -$900000.0 in Q2 2023.
  • The 4-year median for Exchange Rate Effect is $106000.0 (2024), against an average of $4384.6.
  • The widest annual swing landed in 2024, when Exchange Rate Effect slumped 210.39%; it then jumped 470.0% in 2026.
  • Tracing GYRE's Exchange Rate Effect over 4 years: stood at $231000.0 in 2023, then tumbled by 210.39% to -$255000.0 in 2024, then jumped by 149.8% to $127000.0 in 2025, then jumped by 124.41% to $285000.0 in 2026.
  • Per Business Quant, the three latest GYRE Exchange Rate Effect figures stand at $285000.0 (Q1 2026), $127000.0 (Q4 2025), and $117000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Exchange Rate Effect (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 3.60 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -2.70 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -40.30 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -900,000.00
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -7.06 Mn
10 Gyre Therapeutics 532.38 Mn 518.25 Mn 8.38 Mn 285,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 285,000.00
Mar 31, 2026 285,000.00
Dec 31, 2025 127,000.00
Dec 31, 2025 127,000.00
Sep 30, 2025 117,000.00
Sep 30, 2025 117,000.00
Jun 30, 2025 49,000.00
Jun 30, 2025 49,000.00
Mar 31, 2025 50,000.00
Mar 31, 2025 50,000.00
Dec 31, 2024 -255,000.00
Dec 31, 2024 -255,000.00
Sep 30, 2024 106,000.00
Sep 30, 2024 106,000.00
Jun 30, 2024 -78,000.00
Jun 30, 2024 -78,000.00
Mar 31, 2024 -46,000.00
Mar 31, 2024 -46,000.00
Dec 31, 2023 231,000.00
Dec 31, 2023 231,000.00
Sep 30, 2023 171,000.00
Sep 30, 2023 171,000.00
Jun 30, 2023 -900,000.00
Jun 30, 2023 -900,000.00
Mar 31, 2023 200,000.00
Mar 31, 2023 200,000.00